RT-PCR demonstrated that expression of Cyr61
mRNA was higher in the primary
carcinoma (84.6%, 22/26) and the metastatic foci (88.9%, 24/27) than in the non-
tumor control samples (5/11; P < 0.05, respectively). Cyr61 gene
mRNA expression levels were (2.76 +/- 5.50) x 10(-5), (14.61 +/- 20.64) x 10(-5), and (18.46 +/- 26.38) x 10(-5) by 2(-DeltaCt) in the control mucosa samples, primary
carcinomas and metastatic tissues respectively. The level was higher in the primary
carcinomas and metastatic tissues than that of the non-
tumor gastric mucosa (P < 0.05, respectively); however, there was no significant difference between the metastatic tissues and the primary
carcinomas (P > 0.05). Immunohistochemistry revealed that of the 99 cases, there was a high expression of Cyr61 and
NF-kappaB protein, 56.6% (56/99) and 55.6% (55/99) respectively. There was correlation of Cyr61 and
NF-kappaB protein expressions with the depth of
tumor and vascular invasion, as well as the development of
lymph node metastasis, and TNM staging (P < 0.05, respectively), besides, the expression of
NF-kappaB also correlated with the
tumor diameter (P < 0.05). Cyr61 expression was positively correlated with
NF-kappaB expression in gastric
carcinoma (P < 0.05); the mean survival time in cases with a high expression level of Cyr61 and
NF-kappaB protein was significantly shorter than those with a low expression level (P < 0.05).
CONCLUSIONS: